SBIR/STTR Research Award

SBIR Phase I: Development of rod-shaped drug delivery nanoparticles for in-space manufacturing

Award identifier df6ac13c82e85abdc285dd88f0174333a0b3ea154903a8a2b0ff3d4fcf35ce04Awarding agency National Science Foundation

Award amount

$274,990

Program and phase

SBIR · Phase I

Award year

2025

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
National Science Foundation
Branch
Not reported
Recipient company
EASCRA BIOTECH, INC
Proposal award date
2024-12-06
Contract end date
2025-11-30
UEI
NDU4YKLLPTQ1
Solicitation number
NSF 23-515
Topic code
SP

Research abstract

The broader impact of this Small Business Innovation Research (SBIR) Phase I project is its potential to transform the solid tumor cancer treatment market, projected to reach $424.6 billion by 2027. The project aims to advance the regulatory pathway for space-made medicines by using Janus base nanoparticles (JBNps) as a test case to demonstrate comparability with Earth-made versions. This step is crucial for the commercialization of space-made therapeutics, addressing challenges in drug delivery for solid tumors and advancing oncology biotherapeutics. Additionally, the project will boost U.S. dominance in the space economy, drive innovation and economic growth in biotech, and enhance the nation’s global competitiveness. It could lead to advanced, safer therapies for various diseases and contribute to fostering a diverse American STEM (Science, Technology, Engineering, and Mathematics) workforce. Beyond its technological benefits, this project emphasizes diversity, education, and community outreach, promising broader societal and environmental benefits. Ultimately, it holds potential for positive impacts on the LEO (Low Earth Orbit) commercial space economy and global healthcare. This Small Business Innovation Research (SBIR) Phase I project aims to tackle the urgent need for advanced drug delivery systems capable of effectively targeting solid tumors. Current lipid nanoparticles (LNPs), while widely used, face challenges in penetrating the dense extracellular matrix (ECM) of tumors. Eascra’s project focuses on creating a regulatory pathway to commercialize space-made Janus base nanoparticles (JBNps). These nanoparticles, with their nano-rod morphology and DNA-mimicking chemistry, offer improved tumor penetration, effective treatment, and minimal toxicity. Additionally, JBNps maintain drug stability and bioactivity at room temperature, overcoming the cold storage challenges faced by LNPs. Phase I will advance the regulatory approval pathway, laying the groundwork

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

2 SBIR/STTR records share this UEI (2024–2025). Reported award amounts total $349,964. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Defense, National Science Foundation

Agency intelligence

National Science Foundation

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.